Company / R&D Expense
Acadia Pharmaceuticals R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$328.8M
FY2025
5-year range
$239.4M / $361.6M
FY2021-FY2025
Trend
+8.4%
vs FY2024
Sector context
#54 of 210
Health Care
What the data says
At $329M, Acadia Pharmaceuticals's r&d expense ranks #54 of 210 in the Health Care sector. R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $329M.
Based on SEC 10-K filings.
$329M in FY2025 with a 5-year CAGR of +0.6%.
Declined from $352M to $329M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -3.1%
- 5-Year CAGR
- +0.6%
- 10-Year CAGR
- -
Sector benchmark
#54 of 210 in Health CareTop 26% of 210This company $328.8M Sector average $644.0M
▼
-48.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.6%, indicating consistent growth.
- In FY2025, r&d expense increased 8.4% year-over-year.
- Ranks #54 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $328.8M | +8.4% |
| FY2024 | $303.2M | -13.8% |
| FY2023 | $351.6M | -2.8% |
| FY2022 | $361.6M | +51.0% |
| FY2021 | $239.4M | -25.0% |
| FY2020 | $319.1M | +32.8% |
| FY2019 | $240.4M | +28.4% |
| FY2018 | $187.2M | +25.5% |
| FY2017 | $149.2M | +50.3% |
| FY2016 | $99.3M | +34.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026